NCT07652697已完成1 期
A Phase 1, Open-Label, Randomized, Single Dose Three-Way Crossover Study to Evaluate the Bioequivalence of, and the Effect of Food on, ABX-002 in Healthy Adult Participants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
研究概览
简要总结
The goal of this study is to assess the bioequivalence (BE) between the liquid formulation and the new solid formulation of ABX-002 under fasting conditions and to evaluate the effect of food on the pharmacokinetics (PK) of the new solid formulation of ABX-002.This study design is consistent with FDA guidelines for the assessment of BE.
This was an open label, randomized, single dose, three-way crossover BE and food-effect study. Therefore, the total number of participants in this study was 18.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
- •BMI ≥ 18.0 and ≤ 32.0 kg/m2 and minimum weight of 50 kg at the screening visit
- •Medically healthy, as deemed by the PI or designee, with no clinically significant medical history, or clinically significant abnormalities in physical examination, clinical laboratory profiles, and vital signs
- •Capable of providing written informed consent, able to understand the nature of the trial and, in the opinion of the PI or designee, able to follow all protocol requirements including the schedule of assessments
排除标准
- •Mentally or legally incapacitated or had significant emotional problems at the time of the screening visit or expected during the conduct of the study
- •History of any illness that, in the opinion of the PI or designee, might have confounded the results of the study or posed an additional risk to the participant
- •History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
- •History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds
- •History of thyroid disease
- •History or presence of Clinically significant cataract, glaucoma, severe ocular trauma, inflammatory eye disease, or prior ophthalmic surgical procedures or laser surgery in either eye.
- •Clinically significant abnormalities on 12-lead ECG at the screening visit
- •Positive urine drug or alcohol results at the screening visit or check-in
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Single Dose Two Period Oral Bioequivalence Study Comparing Resmetirom Tablets 100 mg in Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2026/02/104326FDC Limited18
已完成
不适用
A Single Dose Two Period Study Comparing Cabozantinib 60 mg Tablets In Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2025/08/092950BDR pharmaceuticals International Pvt Ltd18
尚未招募
不适用
An Open Label Single Dose Two Period Oral Bioequivalence Study Comparing Zifi O Tablets Cefixime 200 mg and Ofloxacin 200 mg Tablets in Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2026/01/100801FDC Limited46
尚未招募
不适用
An Open Label Two Period Study Comparing ZIFI 400 Cefixime Tablets IP 400 mg in Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2026/01/102587FDC Limited46
尚未招募
不适用
An Open Label Single Dose Four Period Oral Bioequivalence Study Comparing Mesalamine Delayed-Release Tablets 1.2g In Healthy Adult Human Subjects Under Fed ConditionsCTRI/2025/12/099703Incepta Pharmaceuticals Ltd16